Drugs / TRICHLOROTELLURATE
TRICHLOROTELLURATE
also known as
AS101 · Ammonium trichloro(dioxoethylene-o,o'-)tellurate · AMMONIUM TRICHLOROTELLURATE · Ossirene
Small molecule targets IL10 via inhibition
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001006 | ? → Mar 1993 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01555112 | Mar 2012 → Jul 2013 | anogenital human papillomavirus infection | BioMAS Ltd | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01010373 | Jan 2015 → Jan 2016 | acute myeloid leukemia, myelodysplastic syndrome | BioMAS Ltd | Suspended | No outcome recorded |
| Phase 2 | NCT00926354 | Aug 2009 → Aug 2010 | thrombocytopenia | BioMAS Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT00927212 | Jun 2009 → Sep 2010 | atopic eczema | BioMAS Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT00788424 | Nov 2008 → Feb 2010 | psoriasis | BioMAS Ltd | Withdrawn | No outcome recorded |
| Phase 2 | NCT00418249 | — | alopecia | Rabin Medical Center | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00002266 | — | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| — | NCT00002013 | — | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| — | NCT00002033 | — | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03216538 Comparator | Oct 2018 → May 2020 | wet macular degeneration | Feramda | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01943630 Comparator | Jan 2015 → May 2017 | anogenital human papillomavirus infection | BioMAS Ltd | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRICHLOROTELLURATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4597200 ↗ |
| Known as | Ammonium trichloro(dioxoethylene-o,o'-)tellurate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4597200 ↗ |
| Known as | AMMONIUM TRICHLOROTELLURATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4597200 ↗ |
| Known as | AS101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01010373 ↗ |
| Known as | Ossirene | ChEMBL registry synonym — accepted as the source's own label CHEMBL4597200 ↗ |
| Action | Inhibit | “direct inhibition of the anti-inflammatory cytokine IL-10” NCT00926354 ↗ |
| Modality | Small molecule | “synthetic organic compound” NCT00001006 ↗ |
| Route | Intravenous | “Patients are given intravenous infusions of AS-101 3 times a week for 12 weeks.” NCT00001006 ↗ |
| Target | IL10 | “direct inhibition of the anti-inflammatory cytokine IL-10” NCT00926354 ↗ |